Impact and prospects of cannabidiol in the dermatological industry

Abstract

Cannabidiol (CBD) has emerged as a high-value compound in the dermatological industry due to its antioxidant, anti-inflammatory and healing properties. However, its incorporation into cosmetic and pharmaceutical products faces regulatory and technical challenges. The present study aims to analyze the impact and prospects of CBD in the dermatological industry, considering scientific, technological, economic and regulatory aspects. To this end, a systematic review of literature published between 2019 and 2024 in databases such as Scopus, PubMed and Web of Science was conducted. Studies on clinical efficacy, extraction methods, regulations and market trends were included. The findings reveal that supercritical CO₂ extraction is the most efficient technique to obtain high-purity CBD. Likewise, clinical studies have demonstrated its efficacy in the treatment of conditions such as psoriasis and acne, although its transdermal bioavailability remains a challenge. On the regulatory side, significant fragmentation between regions was identified, which makes it difficult to standardize its commercialization. Finally, the CBD market in dermatology shows accelerated growth with a projection of 3.5 billion dollars by 2026, despite restrictions in advertising and regulations. In conclusion, CBD represents a promising alternative in dermatology, with growing evidence on its therapeutic benefits. However, its heterogeneous regulation and the technical challenges in its cutaneous absorption require further research and clear policies for its effective integration in the industry.